Liposome Patents (Class 977/907)
-
Patent number: 9028863Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.Type: GrantFiled: April 26, 2004Date of Patent: May 12, 2015Assignee: The Penn State Research FoundationInventors: Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
-
Patent number: 9011710Abstract: Methods are disclosed for synthesizing nanocomposite materials including ferromagnetic nanoparticles with polymer shells formed by controlled surface polymerization. The polymer shells prevent the nanoparticles from forming agglomerates and preserve the size dispersion of the nanoparticles. The nanocomposite particles can be further networked in suitable polymer hosts to tune mechanical, optical, and thermal properties of the final composite polymer system. An exemplary method includes forming a polymer shell on a nanoparticle surface by adding molecules of at least one monomer and optionally of at least one tethering agent to the nanoparticles, and then exposing to electromagnetic radiation at a wavelength selected to induce bonding between the nanoparticle and the molecules, to form a polymer shell bonded to the particle and optionally to a polymer host matrix. The nanocomposite materials can be used in various magneto-optic applications.Type: GrantFiled: April 1, 2010Date of Patent: April 21, 2015Assignee: Arizona Board of Regents on behalf of the University of ArizonaInventors: Palash Gangopadhyay, Alejandra Lopez-Santiago, Robert A. Norwood
-
Patent number: 8999295Abstract: Provided herein is a composition, a method, and a system for delivering a functional molecule to the cytosol of a cell, comprising a liposome configured to be taken into a cell, including by a process selected from the group consisting of endocytosis, pinocytosis or phagocytosis, the liposome comprising a phase transforming liquid with vapor pressure capable of forming a gas at low pressure, said liquid being associated with the liposome, and the liposome further comprising at least one functional molecule selected from the group consisting of a therapeutic molecule, a detectable label, and a targeting molecule.Type: GrantFiled: November 5, 2010Date of Patent: April 7, 2015Assignee: Brigham Young UniversityInventors: William G. Pitt, Ghaleb Husseini
-
Patent number: 8853280Abstract: The present invention provides compositions comprising allylamine drug compounds for topical treatment of fungal infections of the skin and skin appendages. In some embodiments a positive charge and enhancers are used in the compositions to allow for increased penetration of the active ingredient through skin and skin appendages. In some embodiments the positively charged active ingredients are either dissolved in the vehicle directly or dissolved in a plurality of beads suspended in the vehicle. The present invention also provides methods for making compositions comprising an allylamine drug compound, and methods of using such compositions for the treatment of fungal infections of the skin and skin appendages.Type: GrantFiled: October 4, 2011Date of Patent: October 7, 2014Assignee: Biophile Corporation, Ltd.Inventors: Pichit Suvanprakorn, Panida Vayumhasuwan, Nardo Zaias
-
Patent number: 8852472Abstract: The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.Type: GrantFiled: December 27, 2005Date of Patent: October 7, 2014Assignee: Silence Therapeutics GmbHInventors: Oliver Keil, Jörg Kaufmann
-
Patent number: 8821872Abstract: Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer.Type: GrantFiled: May 3, 2010Date of Patent: September 2, 2014Inventors: Jill P. Smith, Gail L. Matters, Neil D. Christensen, John F. Harms
-
Patent number: 8790691Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.Type: GrantFiled: May 26, 2009Date of Patent: July 29, 2014Assignee: The University of British ColumbiaInventors: Pieter Cullis, Marcel Bally, Marco Ciufolini, Norbert Maurer, Igor Jigaltsev
-
Publication number: 20140170227Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 nm to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.Type: ApplicationFiled: September 26, 2013Publication date: June 19, 2014Applicant: Dermazone Solutions, Inc.Inventor: Michael W. Fountain
-
Publication number: 20140170226Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 nm to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.Type: ApplicationFiled: September 26, 2013Publication date: June 19, 2014Applicant: Dermazone Solutions, Inc.Inventor: Michael W. Fountain
-
Patent number: 8753673Abstract: The invention provides a liposome composition for delivering high pay-load of a therapeutic agent to neovascularization sites of the eyes in a patient in need thereof. The liposome composition for entrapping the therapeutic agent comprises a particle forming component composed of a variety of vesicle-forming lipids, and an agent-carrying component able to form a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction; wherein the liposome composition comprising the therapeutic agent has a mean particle diameter of about 30 to 200 nm and may accumulate at the neovascularization sites of the eyes 24 hours after the intravenous administration of the liposome composition comprising the therapeutic agent to the patient. A method for delivering the therapeutic agent to the eyes in a patient with this liposome composition is also provided.Type: GrantFiled: May 23, 2006Date of Patent: June 17, 2014Assignees: Taiwan Liposome Co. Ltd., TLC Biopharmaceuticals, Inc.Inventors: Jun-Jen Liu, Chi-Chun Lai, Yun-Long Tseng, Luke S. S. Guo, Keelung Hong
-
Patent number: 8691750Abstract: The present invention provides novel amino-lipids, compositions comprising such amino-lipids and methods of producing them. In addition, lipid nanoparticles comprising the novel amino-lipids and a biologically active compound are provided, as well as methods of production and their use for intracellular drug delivery.Type: GrantFiled: May 8, 2012Date of Patent: April 8, 2014Assignee: Axolabs GmbHInventors: Rainer Constien, Anke Geick, Philipp Hadwiger, Torsten Haneke, Ludger Markus Ickenstein, Carla Alexandra Hernandez Prata, Andrea Schuster, Timo Weide
-
Patent number: 8623414Abstract: A composition comprising a lipid and copolymer of styrene and maleic acid, wherein the copolymer of styrene and maleic acid is non-alternating, and wherein the polymer and lipid are in the form of macromolecular assemblies.Type: GrantFiled: May 31, 2006Date of Patent: January 7, 2014Assignee: Malvren Cosmeceutics LimitedInventor: Stephen Tonge
-
Patent number: 8597678Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.Type: GrantFiled: December 22, 2006Date of Patent: December 3, 2013Assignee: Dermazone Solutions, Inc.Inventor: Michael W. Fountain
-
Publication number: 20130295159Abstract: A system and method for optimizing the systemic delivery of growth-arresting lipid-derived bioactive drugs or gene therapy agents to an animal or human in need of such agents utilizing nanoscale assembly systems, such as liposomes, resorbable and non-aggregating nanoparticle dispersions, metal or semiconductor nanoparticles, or polymeric materials such as dendrimers or hydrogels, each of which exhibit improved lipid solubility, cell permeability, an increased circulation half life and pharmacokinetic profile with improved tumor or vascular targeting.Type: ApplicationFiled: November 9, 2012Publication date: November 7, 2013Inventors: Mark Kester, Thomas Stover, Tao Lowe, James H. Adair, Young Shin Kim
-
Patent number: 8569239Abstract: A delivery system. The delivery system includes a carrier or an active compound and a glutathione or a glutathione derivative grafted thereon. The invention also provides a compound including a moiety comprising a vitamin E derivative or a phospholipid derivative, a polyethylene glycol (PEG) or a polyethylene glycol derivative bonded thereto, and a glutathione (GSH) or a glutathione derivative bonded to the polyethylene glycol or the polyethylene glycol derivative.Type: GrantFiled: March 11, 2010Date of Patent: October 29, 2013Assignee: Industrial Technology Research InstituteInventors: Ae-June Wang, Chi-Heng Jian, Shyh-Dar Li, Yi-Fong Lin, Shih-Jr Liu
-
Patent number: 8545875Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.Type: GrantFiled: April 10, 2012Date of Patent: October 1, 2013Assignee: Dermazone Solutions, Inc.Inventor: Michael W. Fountain
-
Patent number: 8545874Abstract: Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.Type: GrantFiled: May 3, 2010Date of Patent: October 1, 2013Assignee: Dermazone Solutions, Inc.Inventor: Michael W. Fountain
-
Publication number: 20130236530Abstract: A pain reliever comprised of dextrose, aloe vera concentrate, and some or all of the following ingredients: propylene glycol, caprylic/capric tryglicerides, sodium chloride (or acetic acid), a homeopathic anti-inflamatory extract, Dimethyl Sulfone (or Methylsulfonylmethane (MSM)), cetyl myristoleate, and a pitcher plant extract. The resulting compositions are a water-based solution and two gel composition applied to the epidermis of mammals for relieving pain.Type: ApplicationFiled: March 9, 2012Publication date: September 12, 2013Inventor: Howard Rosen
-
Patent number: 8506993Abstract: According to some embodiments, the present invention provides compositions and methods for making and using multifunctional polymerized liposomes finding relevant application in medical sciences, particularly in bioimaging, diagnostics, drug delivery, and drug formulation. The compositions and methods involve lipids that are both polymerizable and have a “clickable” group that provides the ability to functionalize via a click reaction with various functional moieties useful for the above-listed applications.Type: GrantFiled: August 14, 2008Date of Patent: August 13, 2013Assignee: University of HoustonInventors: Chengzhi Cai, Guoting Qin, Amit Kumar
-
Patent number: 8491928Abstract: Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.Type: GrantFiled: October 9, 2012Date of Patent: July 23, 2013Assignee: Galderma S.A.Inventors: Claire Mallard, Lara Baudonnet
-
Patent number: 8466122Abstract: The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.Type: GrantFiled: September 16, 2011Date of Patent: June 18, 2013Assignee: Protiva Biotherapeutics, Inc.Inventors: James Heyes, Mark Wood, Alan Martin
-
Publication number: 20130115274Abstract: What is described is a method for preparing a liposome that efficiently encapsulates a negatively charged therapeutic polymer, e.g., siRNA. The process involves preparing a lipid mixture comprising a cationic lipid in a water miscible organic solvent, such as ethanol, at a concentration of 2.3 mg/ml, and adding this solution to the polymer dissolved in water to a final concentration of 35% ethanol in water. The final charge ratio of drug:lipid is 1:2.5. The resulting nanoparticles have a mean size of 50 to 150 nm.Type: ApplicationFiled: November 5, 2012Publication date: May 9, 2013Applicant: NITTO DENKO CORPORATIONInventor: Nitto Denko Corporation
-
Publication number: 20130115269Abstract: This invention describes the use of anti-TNF-a antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-TNF-a coated liposomes. The anti-TNF-a coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with anti-TNF-a antibody and used to deliver the drug to the site of inflammation. Also in lieu of the anti-TNF-a antibody other TNF-a binding agents such as aptamers and binding peptides may be used to coat the various nanosized drug delivery vehicles such as micelles, dendrimers, nanocapsules and nanoparticles in order to deliver the drug to the site of inflammation.Type: ApplicationFiled: July 18, 2012Publication date: May 9, 2013Inventors: Henry John Smith, James Roger Smith
-
Patent number: 8431545Abstract: The present invention relates to a block copolymer containing an uncharged hydrophilic polymer chain block and a cationic polyamino acid chain block, wherein the hydrophilic polymer chain block is covalently bound to one end of the main chain of the polyamino acid chain block, and the hydrophobic group is covalently bound to the side chains of not less than 10% and not greater than 70% of amino acid repeating units in the polyamino acid chain block. This block copolymer forms a stable aggregate with siRNA, a small-molecule nucleic acid, under a physiological condition.Type: GrantFiled: March 6, 2009Date of Patent: April 30, 2013Assignee: The University of TokyoInventors: Kazunori Kataoka, Nobuhiro Nishiyama, Atsushi Ishii, Yasuki Kato, Kanjiro Miyata, Hyunjin Kim, Hiroyasu Takemoto
-
Publication number: 20130102993Abstract: A liposome including an elastin-like polypeptide (ELP) and a tumor cell targeting material, a pharmaceutical composition including the liposome, and a method of delivering an active agent to a target site using the liposome.Type: ApplicationFiled: September 10, 2012Publication date: April 25, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventors: Min Sang KIM, Hyun Ryoung KIM, Jae Chan PARK, Su Young CHAE, Sang Joon PARK
-
Publication number: 20130102898Abstract: A liposome comprising elastin-like polypeptides, a pharmaceutical composition comprising the liposome, and a method of delivering active agents to a target site using the liposome.Type: ApplicationFiled: October 19, 2012Publication date: April 25, 2013Applicant: SAMSUNG ELECTRONICS CO., LTD.Inventor: Samsung Electronics Co., Ltd.
-
Publication number: 20130101663Abstract: This invention describes the use of sTNF-R as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the sTNF-R coated liposomes. The sTNF-R coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with sTNF-R and used to deliver the drug to the site of inflammation.Type: ApplicationFiled: August 6, 2012Publication date: April 25, 2013Inventors: Henry John Smith, James Roger Smith
-
Publication number: 20130089599Abstract: This invention relates to a method to provide immediate, direct and controlled time release of an effective amount of therapeutics to a wound site for a prolonged period. The pharmaceutical formulation comprising a plurality of nanoparticles, said nanoparticles encapsulating a therapeutically effective amount of one or more antibacterial agents, and an application of the formulation to an implant before surgery provide for extended release of said antibacterial agents.Type: ApplicationFiled: June 10, 2012Publication date: April 11, 2013Applicant: The United States of America as Represented by the Secretary of the NavyInventors: Mauris N. DeSilva, Karen O'Connor, Amer Tiba
-
Patent number: 8410260Abstract: Novel double-stranded RNA oligonucleotides are useful for decreasing tyrosinase expression, have cosmetic and/or pharmaceutical applications, for example are useful skin depigmenting or anti-browning agents, and can be associated with cationic particles less than or equal to 1 ?m in size, having a zeta potential of from 10 to 80 mV.Type: GrantFiled: October 15, 2008Date of Patent: April 2, 2013Assignee: L'OrealInventors: Christine Collin-Djangone, Jean-Thierry Simonnet
-
Publication number: 20130058994Abstract: The present invention provides compositions and methods for the treatment of multiple sclerosis. Among others, the invention provides compositions of immunodominant peptides of myelin basic protein encapsulated in mannosylated liposomes. In a specific embodiment, the compositions comprise mylein basic protein (MBP) peptides MBP(46-62), MBP(124-139), and MBP(147-170).Type: ApplicationFiled: April 11, 2012Publication date: March 7, 2013Inventors: Alexander Gabivov, Alexey Belogurov, Natalia Ponomarenko, Ivan Smirnov, Andrew Bacon, Gregory Gregoriadis
-
Publication number: 20130039969Abstract: There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.Type: ApplicationFiled: April 11, 2012Publication date: February 14, 2013Applicant: Biolipox ABInventors: Lena Pereswetoff-Morath, Anders Carlsson
-
Publication number: 20130039974Abstract: The present invention is directed to antibodies binding to the MUC1 cytoplasmic domain and methods of using such antibodies to treat, diagnose, detect and monitor cancers that express the MUC1 antigen.Type: ApplicationFiled: August 10, 2012Publication date: February 14, 2013Inventors: Donald W. Kufe, Surender Kharbanda
-
Publication number: 20130039977Abstract: Pharmaceutically acceptable liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution and significantly reduced side effects over those produced by oral administration or parenteral administration of free drug. The formulations are useful as part of stem cell and/or bone marrow transplant conditioning regimens. A method of treatment of a mammal by use of such formulations.Type: ApplicationFiled: October 18, 2012Publication date: February 14, 2013Applicant: BUSULIPO ABInventor: BUSULIPO AB
-
Publication number: 20130034599Abstract: Articles, compositions, kits, and methods relating to nanostructures, including synthetic nanostructures, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanostructure core may be surrounded by a shell including a material, such as a lipid bilayer, and may include other components such as oligonucleotides. In some embodiments, the structures, when introduced into a subject, can be used to deliver nucleic acids and/or can regulate gene expression. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions. In some cases, the structures are both a therapeutic agent and a diagnostic agent.Type: ApplicationFiled: January 19, 2011Publication date: February 7, 2013Applicant: NORTHWESTERN UNIVERSITYInventors: C. Shad Thaxton, Chad A. Mirkin, Kaylin M. McMahon, Sushant Tripathy, Raja Kannan Mutharasan, David M. Leander, Andrea Luthi
-
Publication number: 20130028959Abstract: Formulations for preventing the sexual transmission of the HIV virus are provided. In one embodiment, the formulations contain un-conjugated liposomes whose physicochemical properties allow binding to the HIV virus. The liposomes are made up of natural or synthetic lipids, alone or in combination. Preferably, the liposomes are made entirely of cardiolipin. In other embodiments the liposomes are modified to contain Hgands which bind HIV. The method for preventing the sexual transmission of the HIV virus includes self-administration of a formulation containing an effective amount of liposomes which bind to the HIV virus to the surface of a mucosal membrane prior to intercourse.Type: ApplicationFiled: December 16, 2010Publication date: January 31, 2013Applicants: Massachusetts Institute of Technology, Children's Medical Center CorporationInventors: Nikita Kiran Malavia, Daniel S. Kohane
-
Publication number: 20130028962Abstract: Control of the fusion activity of liposomes by adsorbing biocompatible nanoparticles to the outer surface of phospholipid liposomes is disclosed. The biocompatible nanoparticles effectively prevent liposomes from fusing with one another. Release of cargo from the liposome is accomplished via trigger mechanisms that include pH triggers, pore forming toxing triggers and photosensitive triggers. Dermal drug delivery to treat a variety of skin diseases such as acne vulgaris and staph infections is contemplated.Type: ApplicationFiled: September 7, 2012Publication date: January 31, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Liangfang Zhang, Dissaya Pornpattananangkul, Chun-Ming E. Huang
-
THERAPEUTIC COMPOSITIONS AND METHODS FOR DELIVERY OF ACTIVE AGENTS CLEAVABLY LINKED TO NANOPARTICLES
Publication number: 20130004523Abstract: Various embodiments of the present invention pertain to therapeutic compositions that comprise: (1) an active agent (e.g., paclitaxel); and (2) a nanoparticle (e.g., gold nanoparticle). In such embodiments, the active agent is covalently linked to the nanoparticle through a cleavable linker (e.g., a linker containing a hydrazone species). Other embodiments of the present invention pertain to methods of treating a condition in a subject by administering the above-described therapeutic compositions to the subject.Type: ApplicationFiled: December 9, 2010Publication date: January 3, 2013Applicant: William Marsh Rice UniversityInventors: Eugene Zubarev, Jacob Gibson -
Publication number: 20130004561Abstract: The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin, and wherein said prevention or treatment is by oral delivery of the antibody composition. Also provided is a pharmaceutical composition of ovine antibodies for oral delivery, which further comprises one or more means for protecting the antibodies from trypsin and/or chymotrypsin and/or stomach acid.Type: ApplicationFiled: December 6, 2010Publication date: January 3, 2013Inventors: Clifford Shone, April Roberts, John Landon
-
Publication number: 20120321683Abstract: The aim of the invention is to preserve the morphology of bicelles in high-water-content environments. For this purpose, the invention relates to a liposome comprising, in its internal aqueous medium, at least one bicelle. The bicelles concentration in said aqueous means is between 5 and 25% dry weight in relation to the end liposome. The invention also relates to the use of said liposomes for the encapsulation of active principles, as well as to the use thereof as a medicament or to produce a cosmetic product. The invention further relates to the method for obtaining said liposomes.Type: ApplicationFiled: February 28, 2011Publication date: December 20, 2012Inventors: Alfons De La Maza Rivera, Lucyana Barbosa, Olga López Serrano, Mercedes Cocera Núñez, Gelen Rodríguez Delgado, Laia Rubio Toledano, Ana María Planas Obradors, Guadalupe Soria Rodríguez
-
Publication number: 20120321698Abstract: Inhalable pharmaceutical compositions can include an aqueous dispersion of particles including a hydrophobic bioactive agent (e.g., CoQ10) suitable for continuous aerosolization. Due to their chemical composition and methods of manufacture, the pharmaceutical compositions exhibit distinctive physicochemical properties that provide advantageous aerosol transmission and output.Type: ApplicationFiled: June 18, 2012Publication date: December 20, 2012Inventors: Niven Rajin Narain, John Patrick McCook
-
Publication number: 20120315322Abstract: The present disclosure provides compositions and methods of treating Alzheimers Disease. In an aspect, a nanoparticle is paired to one or more genetic materials that regulates inflammation in a microenvironment. Such nanoparticles can be used to target predefined target cell types in connection with treatment of at least one of the following Alzheimer's disease, Pick's disease, Lewy Body disease, or Idiopathic dementia.Type: ApplicationFiled: June 8, 2012Publication date: December 13, 2012Applicant: NNANOAXIS, LLCInventors: Krishnan Chakravarthy, Robert Spengler, Tracey Ignatowski, Siddhartha Venkata Kamisetti
-
Publication number: 20120308642Abstract: Compositions are disclosed of combinations of small interfering RNAs (siRNA) that can inhibit the replication of hepatitis C virus (HCV) in liver cells, along with methods of co-administering the siRNAs to subjects. Further, methods are disclosed for improving the delivery of nucleic acids to the liver.Type: ApplicationFiled: May 29, 2012Publication date: December 6, 2012Applicants: XAVIER UNIVERSITY OF LOUISIANA, THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventors: Srikanta DASH, Tarun K. MANDAL, Partha K. CHANDRA, Anup KUNDU, Sidhartha HAZARI
-
Patent number: 8323686Abstract: Articles, compositions, kits and methods relating to nanostructures, including those that can sequester molecules such as cholesterol, are provided. Certain embodiments described herein include structures having a core-shell type arrangement; for instance, a nanoparticle core may be surrounded by a shell including a material, such as a lipid bilayer, that can interact with cholesterol and/or other lipids, and an apolipoprotein may be bound to at least the outer surface of the shell. In some embodiments, the structures, when introduced to a subject, can sequester cholesterol and/or other lipids and remove them from circulation. Accordingly, the structures described herein may be used to diagnose, prevent, treat or manage certain diseases or bodily conditions, especially those associated with abnormal lipid levels.Type: GrantFiled: April 24, 2009Date of Patent: December 4, 2012Assignee: Northwestern UniversityInventors: Chad A. Mirkin, C. Shad Thaxton, David A. Giljohann, Weston Daniel
-
Patent number: 8318199Abstract: Disclosed herein is a composite of a nanoscale particle size. The composite is able to specifically deliver therapeutic agents such as therapeutic nucleic acids or drugs to the liver and selectively release them into hepatic cells to manifest potent therapeutic effects of the therapeutic agents. The composite may be comprised of an apolipoprotein A-1 and a liposome-forming material. A composition containing the composite and a pharmaceutically acceptable carrier is disclosed.Type: GrantFiled: June 1, 2010Date of Patent: November 27, 2012Assignee: Mogam Biotechnology Research InstituteInventors: Meehyein Kim, Soo In Kim, Duckhyang Shin, Mahnhoon Park
-
Publication number: 20120288555Abstract: Antiproliferative compositions that include CLEFMA, as well as liposomal compositions containing said antiproliferative compositions, are disclosed. Also disclosed are methods of making and using the antiproliferative compositions and liposomal compositions.Type: ApplicationFiled: October 24, 2011Publication date: November 15, 2012Inventors: Vibhudutta Awasthi, Pallavi Lagisetty, Hrushikesh Agashe
-
Publication number: 20120282327Abstract: A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.Type: ApplicationFiled: July 13, 2012Publication date: November 8, 2012Inventors: Jih Ru Hwu, Yu-Sern Lin, Chen-Sheng Yeh, Dar-Bin Shieh, Wu-Chou Su
-
Patent number: 8283333Abstract: The present invention provides novel, serum-stable lipid particles comprising one or more active agents or therapeutic agents, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles. More particularly, the present invention provides serum-stable nucleic acid-lipid particles (SNALP) comprising a nucleic acid (e.g., one or more interfering RNA molecules), methods of making the SNALP, and methods of delivering and/or administering the SNALP (e.g., for the treatment of cancer). In particular embodiments, the present invention provides tumor-directed lipid particles that preferentially target solid tumors. The tumor-directed formulations of the present invention are capable of preferentially delivering a payload such as a nucleic acid to cells of solid tumors compared to non-cancerous cells.Type: GrantFiled: June 30, 2010Date of Patent: October 9, 2012Assignee: Protiva Biotherapeutics, Inc.Inventors: Ed Yaworski, Stephen Reid, James Heyes, Adam Judge, Ian MacLachlan
-
Publication number: 20120244206Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: ApplicationFiled: October 22, 2007Publication date: September 27, 2012Inventors: David C. Cipolla, James Blanchard
-
Publication number: 20120231069Abstract: Disclosed herein are nanoparticle, micelle and/or liposome compositions, each comprising a therapeutic agent encapsulated in one or more polymer(s), wherein a vitamin B12 or a derivative thereof is attached to the one or more polymer(s) via a linker group, as well as methods for making and using same.Type: ApplicationFiled: March 7, 2012Publication date: September 13, 2012Inventors: David P. Nowotnik, Ryszard Zarzycki, Paul Sood, N.Rao Ummaneni
-
Publication number: 20120225117Abstract: The present invention provides a liposome production process which enables production of a liposome that has a nano-size particle diameter and a high water-soluble drug encapsulation rate. The process for producing a W1/O/W2 emulsion of the present invention includes the steps of (1) emulsifying an organic solvent (O) that is a volatile organic solvent, an aqueous solvent (W1) and a mixed lipid component (F1) to give a W1/O emulsion; and (2) dispersing the W1/O emulsion produced in step (1) in an aqueous solvent (W2) by use of a porous membrane, to give a W1/O/W2 emulsion, wherein the porous membrane has been surface-treated with a hydrophilic drug so as to allow its surface to have a water contact angle of 0 to 42° in the air.Type: ApplicationFiled: November 15, 2010Publication date: September 6, 2012Applicant: KONICA MINOLTA HOLDINGS, INC.Inventors: Takeshi Isoda, Yasuyuki Motokui, Takeshi Wada